{"title":"奥西替尼诱发皮肤血管炎1例报告及文献复习","authors":"","doi":"10.32932/gecp.2023.10.038","DOIUrl":null,"url":null,"abstract":"A 77-year-old patient with a history of stage IVa (cT4N3M1a) lung adenocarcinoma, treated with osimertinib 80 mg/ day, developed palpable purpura nine days after starting therapy. Skin biopsy revealed leukocytoclastic vasculitis. A complete clinical and lab workup for systemic involvement was unremarkable. The patient suspended osimertinib and started on methylprednisone 1mg/Kg/day. Skin lesions gradually improved. Four weeks apart, the patient resumed","PeriodicalId":484795,"journal":{"name":"Revista do Grupo de Estudos do Cancro do Pulmão","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Osimertinib-induced cutaneous vasculitis: A case report and review of the literature\",\"authors\":\"\",\"doi\":\"10.32932/gecp.2023.10.038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 77-year-old patient with a history of stage IVa (cT4N3M1a) lung adenocarcinoma, treated with osimertinib 80 mg/ day, developed palpable purpura nine days after starting therapy. Skin biopsy revealed leukocytoclastic vasculitis. A complete clinical and lab workup for systemic involvement was unremarkable. The patient suspended osimertinib and started on methylprednisone 1mg/Kg/day. Skin lesions gradually improved. Four weeks apart, the patient resumed\",\"PeriodicalId\":484795,\"journal\":{\"name\":\"Revista do Grupo de Estudos do Cancro do Pulmão\",\"volume\":\"57 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista do Grupo de Estudos do Cancro do Pulmão\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32932/gecp.2023.10.038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista do Grupo de Estudos do Cancro do Pulmão","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32932/gecp.2023.10.038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Osimertinib-induced cutaneous vasculitis: A case report and review of the literature
A 77-year-old patient with a history of stage IVa (cT4N3M1a) lung adenocarcinoma, treated with osimertinib 80 mg/ day, developed palpable purpura nine days after starting therapy. Skin biopsy revealed leukocytoclastic vasculitis. A complete clinical and lab workup for systemic involvement was unremarkable. The patient suspended osimertinib and started on methylprednisone 1mg/Kg/day. Skin lesions gradually improved. Four weeks apart, the patient resumed